The U.S. Food and Drug Administration is nearing a major decision on whether or not they will approve the first ever gene-editing treatment for Sickle Cell Disease.
CGTN's Toni Waterman explains.
For more, check out our exclusive content on CGTN Now and subscribe to our weekly newsletter, The China Report.
Copyright © 2020 CGTN. Beijing ICP prepared NO.16065310-3